Pharmos(PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Israel-Rosen who wrote (1339)	10/7/1998 8:02:00 AM
From: Kirsten	of 1491

The following is a post from Dr. Gabe Fernandez on the Yahoo board ----------------------------------------------------------------------------------------------------------- Data given to consider: 1-Mortality Reduction 26% 2-Significant reduction in increased intracranial pressure (ICP} . as stated this point alone reducing ICP above stated threshold of 25 mm HG. This alone is a very important factor in the care of the head injured victim and would indicate the use on every case of severe injury. 3-The fact that there is no concomittant reduction in systolic blood pressure is of massive importance.the combination of head trauma and shock (lower blood pressure) increases the problems associated with head trauma since with lower blood pressure cerbral perfusion is impaired. Also better blood pressure 13% in the treated group vs 38% in the placebo group,could indicate a factor that may also help the managment of shock(the latter observation is personal) 4-Improved Neurological outcomes was consistently seen among the most severly treated injured patients (lower Glasgow Scale Group}. The higher group of patients in the Glasgow scale or the least severly injured had similar outcomes at the six month periods. This is to be expected. 5-Finally as we knew the product is safe in adults and children. IN summary if the above data is correct without question HU-211 will be an important tool in the armamenterium available for the managment of the severe head trauma victim. Notice that the report didn't discuss the mechanism of action of the product perhaps in the paper this will be discussed at length. This is important in considering the efficacy of this product in other neurological conditions such as strokes etc. Finally as a neurosurgeon the fact that it lowers and aids in the managment of increased intracranial pressure it probably will be indicated in the postoperative complications of brain surgery characterized by brain edema or swellin ex Brain Tumors , Aneurysms etc I would like to post this in the silicon investor area if anyone knows how perhaps Robert can come to help. Sorry about the length of the post but i am excited to no end.. IF TRUE THIS WIll HELP A BIG PROBLEM IN MEDICINE and save a great deal of money in the overall medical costs of the public. Gabe Fernandez M.D.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next